J. Goldman & Co’s AbbVie ABBV Stock Holding History

J. Goldman & Co’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.35M	Buy	+20,000	New	+$4.44M	0.13%	206
2025 Q4	–	Sell	-20,000	Closed	-$4.63M	–	546
2025 Q3	$4.63M	Buy	+20,000	New	+$4.07M	0.12%	206
2025 Q2	–	Sell	-60,000	Closed	-$12.6M	–	439
2025 Q1	$12.6M	Buy	+60,000	New	+$11.7M	0.31%	108
2024 Q4	–	Sell	-20,000	Closed	-$3.95M	–	439
2024 Q3	$3.95M	Buy	+20,000	New	+$3.73M	0.11%	184
2024 Q2	–	Sell	-20,000	Closed	-$3.64M	–	426
2024 Q1	$3.64M	Buy	20,000 +2,500	+14%	+$431K	0.12%	174
2023 Q4	$2.71M	Buy	+17,500	New	+$2.55M	0.11%	168
2022 Q3	–	Sell	-20,000	Closed	-$3.06M	–	376
2022 Q2	$3.06M	Buy	+20,000	New	+$3.06M	0.15%	160

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

J. Goldman & Co's ABBV Position: Q4 2023 in Review

J. Goldman & Co sold out of AbbVie (ABBV) in Q4 2023, closing a stake of 178,591 shares — an estimated $26M sold.

J. Goldman & Co first reported a position in ABBV in Q3 2022 and held it in 3 quarters. The position peaked at $27.3M in Q2 2023. 3,322 funds tracked by Wall St. Rank hold ABBV as of Q4 2023.

J. Goldman & Co reported no remaining AbbVie position as of Q4 2023 after selling out during the quarter.
J. Goldman & Co sold 178,591 AbbVie shares in Q4 2023, an estimated $26M.
J. Goldman & Co first reported a position in AbbVie in Q3 2022 and held it in 3 quarters.
J. Goldman & Co's AbbVie position peaked at $27.3M in Q2 2023.
3,322 funds tracked by Wall St. Rank held AbbVie as of Q4 2023.

Based on J. Goldman & Co's 13F filing for Q4 2023, filed 14 Feb 2024.